Login to Your Account

in the clinic NEWS

Making good on preclinical whispers heard at last year's American Association for the Study of Liver Diseases meeting, Regulus Therapeutics Inc. disclosed interim phase I proof-of-concept data showing that one subcutaneous 2 mg/kg dose of its hepatitis C virus (HCV) candidate RG-101 knocked down HCV RNA in a diverse group of patients.

Regeneron Pharmaceuticals Inc. and Sanofi SA began dosing patients in the first of several planned phase III studies of the potential blockbuster dupilumab (REGN668/SAR231893).
When Celgene Corp. reported that it was shelling out a whopping $710 million up front to little known privately held Nogra Pharma Ltd. to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate to severe Crohn's disease (CD), eyebrows were raised by analysts who follow the company.
More in the clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: